Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application - Part II

International Journal of Toxicology

Volumn 24, Issue SUPPL. 5, 2005, Pages 327-339

  Torrey, Carla E ^a   Wall, Henry G ^b   Campbell, James A ^a   Kwanyuen, Puntipa ^a   Hoivik, Debie J ^a   Miller, Richard T ^a   Allen, Jane S ^c   Jayo, Manuel J ^d   Selinger, Krzysztof ^e   Santostefano, Michael J ^a  

^a GLAXOSMITHKLINE   (United States)

^b EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^c Jane Allen Consulting Inc   (United States)

^d Pathology Associates Inc   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

Author keywords

12 o Tetradecanoylphorbol 13 acetate; Benzene; Carcinogenicity; Clofibrate; Micronucleus; Tg.AC; TPA

Indexed keywords

BENZENE; CLOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOID X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHORBOL DERIVATIVE; TETRADECANOYLPHORBOL 13 ACETATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CARCINOGENICITY; EVALUATION; FEMALE; GENOTOXICITY; HISTOPATHOLOGY; MALE; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MICRONUCLEUS TEST; MOUSE; NONHUMAN; SKIN PAPILLOMA; SKIN TUMOR; TOXICOKINETICS; TRANSGENIC MOUSE; TUMOR MODEL; WILD TYPE; CARCINOGENICITY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; INCIDENCE; KIDNEY; KIDNEY INJURY; LIVER; LIVER INJURY; MICROSCOPY; MOUSE STRAIN; RODENT; SKIN; SPLEEN; SPLEEN INJURY;

ANIMALIA; MUS MUSCULUS; RODENTIA;

ADMINISTRATION, CUTANEOUS; ANIMALS; CARCINOGENICITY TESTS; CLOFIBRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, RAS; MALE; MICE; MICE, TRANSGENIC; PAPILLOMA; PEROXISOME PROLIFERATORS; RISK ASSESSMENT; SKIN NEOPLASMS; TIME FACTORS;

EID: 27544489420     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810500208199     Document Type: Article

References (29)

1. Blain, P. G. 2003. Committee on carcinogenicity of chemicals in food, consumer products and the environment. Statement on ILSI/HESI research programme on alternative cancer models. Toxicol. Pathol. 31:254-257.
2. Cannon, R. E., J. W. Spalding, C. S. Trempus, C. J. Szczesniak, K. M. Virgil, M. C. Humble, and R. W. Tennant. 1997. Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol. Carcinogenesis 20:108-114.
3. Cheung, C., T. E. Akiyama, J. M. Ward, C. J. Nicol, L. Feigenbaum, C. Vinson, and F. J. Gonzalez. 2004. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64:3849-3854.
4. Colitz, C. M. H., D. E. Malarkey, R. P. Woychik, and J. E. Wilkinson. 2000. Persistent hyperplastic tunica vasculosa lentis and persistent hyperplastic primary vitreous in transgenic line TgN3261Rpw. Vet. Pathol. 37:422-427.
5. DeSante, K. A., A. R. Disante, K. S. Albert, D. J. Weber, R. D. Welch, and T. J. Vecchio. 1979. The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate. J. Clin. Pharmacol. 19:721-725.
6. Dunnett, C. W. 1955. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1095-1121.
7. Eastin, W. C., J. H. Mennear, R. W. Tennant, R. W. Stoll, D. G. Branstetter, J. R. Bucher, B. McCullough, R. L. Binder, J. W. Spalding, and J. F. Mahler. 2001. Tg.AC genetically altered mouse: Assay working group overview of available data. Toxicol. Pathol. 29(Suppl):60-80.
8. Isenberg, J. S., L. M. Kamendulis, D. C. Ackley, J. H. Smith, G. Pugh Jr., A. W. Lington, R. H. McKee, and J. E. Klaunig. 2001. Reversibility and persistence of di-2-ethylhexyl phthalate (DEHP)- and phenobarbital-induced hepatocellular changes in rodents. Toxicol. Sci. 64:192-199.
9. Khaliq, M. A., and S. P. Srivastava. 1993. Induction of hepatic polyamines by di(2-ethylhexyl)phthalate in rats. Toxicol. Lett. 66:317-321.
10. Klaunig, J. E., M. A. Babich, K. P. Baetcke, J. C. Cook, J. C. Corton, R. M. David, J. G. DeLuca, D. Y. Lai, R. H. McKee, J. M. Peters, R. A. Roberts, and P. A. Fenner-Crisp. 2003. PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33:655-780.
11. Kluwe, W. M., J. K. Haseman, J. F. Douglas, and J. E. Huff. 1982. The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. J. Toxicol. Environ. Health 10:797-815.
12. Legator, M. S., and B. L. Harper. 1988. Mutagenicity screening/in vitro testing-the end of an era; animal and human studies-the direction for the future. Ann. N. Y. Acad. Sci. 534:833-844.
13. Mahler, J. F., N. D. Flagler, D. E. Malarkey, P. C. Mann, J. K. Haseman, and W. Eastin. 1998. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol. Pathol. 26:501-511.
14. Marsman, D. S., R. C., Cattley, J. G. Conway, and J. A. Popp. 1988. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in rats. Cancer Res. 48:6739-6744.
15. NDA. 1993. Summary of basis for approval, Food and Drug Administration, 19-304.
16. Nesfield, S. R., C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano. 2005a. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse. Int. J. Toxicol. 24:301-311.
17. Nesfield, S. R., T. C. Williams, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, D. Rickert, and M. J. Santostefano. 2005b. Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. Int. J. Toxicol. 24:341-348.
18. Reddy, J. K., S. Rao, and D. E. Moody. 1976. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 36:1211-1217.
19. Robinson, D. E., and J. S. MacDonald. 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol. Pathol. 29(Suppl.):13-19.
20. Storer, R. D., J. E. French, J. Haseman, G. Hajian, E. K. LeGrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz, and K. A. Soper. 2001. P53+/-hemizygous knockout mouse: Overview of available data. Toxicol. Pathol. 29(Suppl.):30-50.
21. Tamaoki, N. 2001. The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol. 29(Suppl.):81-89.
22. Tennant, R. W., J. E. French, and J. W. Spalding. 1995. Identification of chemical carcinogens and assessing potential risk in short term bioassays using transgenic mouse models. Environ. Health Perspect. 103:942-950.
23. Tennant, R. W., J. Spalding, and J. E. French. 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365:119-127.
24. Tennant, R. W., S. Stasiewicz, W. C. Eastin, J. H. Mennear, and J. W. Spalding. 2001. The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol. Pathol. 29(Suppl.):51-59.
25. Tomaszewski, K. E., M. C. Derks, and R. L. Melnick. 1987. Acyl CoA oxidase is the most suitable marker for hepatic peroxisomal changes caused by treatment of F344 rats with di(2-ethylhexyl)phthalate. Toxicol. Lett. 37:203-212.
26. +/- Mouse. Int. J. Toxicol. 24:289-299.
27. Torrey, C. E., H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, and M. J. Santostefano. 2005b. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration - Part I. Int. J. Toxicol. 24:313-325.
28. Trempus, C. S., J. Mahler, H. Ananthaswamy, S. Loughlin, R. Tennant, and J. French. 1998. Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J. Invest. Dermatol. 111:445-451.
29. Yki-Jarvinen, H. 2004. Thiazolidinediones. N. Engl. J. Med. 351:1106-1118.